Omalizumab for Treating Severe Persistent Allergic Asthma (TA278)

Technology Appraisal Guidance No. 278

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in people aged 6 years and older

  • who need continuous or frequent treatment with oral corticosteroids (defined as 4 or  more courses in the previous year), and
  • only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme.

1.2 Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with inhaled high-dose corticosteroids, long-acting beta2 agonists, leukotriene  receptor antagonists, theophyllines, oral corticosteroids, and smoking cessation if clinically  appropriate.

1.3 People currently receiving omalizumab whose disease does not meet the criteria in 1.1  should be able to continue treatment until they and their clinician consider it appropriate to  stop.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Omalizumab for treating severe persistent allergic asthma.

Issue Date: April 2013

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in